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ROLE OF CORNEAL COLLAGEN CROSS-LINKING 
WITH RIBOFLAVIN IN KERATOCONUS 
 
ABSTRACT 
AIM: 
 To evaluate the safety and efficacy of corneal collagen cross-linking with 
riboflavin (C3R) in keratoconus and its role in preventing the disease 
progression. 
MATERIALS AND METHODS: 
 This was a prospective interventional study conducted on patients with 
progressive keratoconus who presented to the Cornea Clinic, at a tertiary eye 
care hospital in Tamilnadu over a 20 month period (April 2011 to November 
2012) with a follow-up of one year were enrolled. The outcome measures such 
as uncorrected visual acuity, best corrected visual acuity, spherical equivalent, 
cylindrical error, keratometry values (Kmax, Kmin, Kavg), and the rate of 
development of complications if any, were analysed at one month, 6 months and 
at one year post-C3R. 
RESULTS: 
 Fifty eyes of 38 patients comprising 20 males (53%) and 18 females 
(47%) with progressive keratoconus with a mean age of 19.2 ± 4.5 years (range: 
11-25 years), were included. Visual acuity improved significantly from the 
baseline till one year of follow-up in all treated eyes. (p<0.0001).There was 
gradual reduction in the keratometry readings throughout the   follow-up period 
in a significant manner (p<0.0001). The demographic factors such as age, gender 
and other pre-operative indices like corneal thickness and the average 
keratometry value did not influence the outcome of this procedure. 
Complications in the form of corneal ulcer developed in two (4%) of the 50 eyes 
in this study, and this was attributed to the use of bandage contact lens post-
procedure. 
CONCLUSION: 
 Corneal collagen cross-linking with riboflavin is a simple, safe and an 
effective modality of treatment for progressive keratoconus with good success 
rate and minimal incidence of complications. However, longer follow-up is 
required for assessing the durability of this procedure and its long term side 
effects. 
Keywords: C3R, corneal collagen cross-linking, keratoconus. 
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INTRODUCTION 
 Corneal ectasia refers to a group of disorders affecting the shape of 
the cornea and includes entities such as keratoconus, keratoglobus, 
pellucid marginal degeneration and iatrogenic causes such as progressive 
post-lasik keratectasia (PPLK). In ectasia, corneal thinning occurs which 
leads to bulging of the cornea, resulting in regular or irregular astigmatism. 
This astigmatism causes reduced visual acuity in these patients. 
 Ectasias are usually bilateral in nature, asymmetric and non- 
inflammatory. The incidence of ectatic disorders of the cornea is higher in 
the young population. Keratoconus is a common ectatic disorder affecting 
the eye and is one of the major causes of reduced vision in this  population.  
 Keratoconus is a bilateral, asymmetric, non-inflammatory, 
progressive   ectasia   that   causes steepening of the cornea. The incidence 
of   this condition in the population is 1 in 2000 and it especially affects 
individuals in their early teens. (Rabinowitz et al., 1998)1. The cornea 
assumes a conical shape most typically inferior to the center, because of 
the ectasia, which leads to an off-center apex, causing irregular 
astigmatism.  
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 Histopathologically, keratoconus exhibits the triad of thinning of the 
corneal stroma, breaks in Bowman’s membrane and deposition of iron in 
the basal layer of the corneal epithelium. 
 Current therapeutic options for keratoconus  includes  spectacle 
correction for myopic astigmatism in early stages, rigid contact lenses, 
scleral contact lenses and customized lens like Rose K lens™ (Menicon 
Co, Ltd, Nagoya, Japan), intra stromal corneal ring segments (INTACS), 
and  lamellar and penetrating keratoplasty. 
 Recently, after a detailed study of the pathogenic mechanisms 
involved in keratectasia, a new technique has emerged, namely corneal 
collagen cross-linking using riboflavin (C3R). The major advantage of this 
technique over all other modalities is that C3R arrests progression of the 
ectasia. (Wollensak et al., 2003)2  
  C3R is also referred as CCL or CXL. This technique was described 
by Theo Seiler, Eberhard Spoerl ( Spoerl E et al., 1998)3  and Wollensak (2) 
at the University of Dresden, Germany. Further studies have been 
conducted by Caporossi  and Roberto Pinelli in Italy and also Brian Boxer 
in the United States of America (USA).This technique increases the 
mechanical and chemical stability of the corneal tissue by creating 
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additional chemical covalent bonds in the corneal stroma by means of 
highly localized photopolymerization. (Wollensak et al., 2006)4  
 C3R involves the sequential use of riboflavin (vitamin B2) and 
ultraviolet light in the A spectrum (UV-A) to induce collagen crosslinking 
in the corneal stroma, thus enhancing its biomechanical rigidity. This leads 
to either slowing down or total arrest of the progression of ectasia (2,4). 
Custom made riboflavin drops used in a concentration of 0.1% act as the 
photosensitiser ; they are non-toxic and soluble in nature. UV-A, having a 
wavelength of   370 nm, is used for exciting the already sensitized cornea, 
because this particular wavelength is strongly absorbed and  also protects 
the deeper layers of the eye ; also, the absorption peak of riboflavin is 
achieved at this wavelength. 
 Riboflavin, upon excitation is converted into a triplet state, which 
gives rise to reactive oxygen species (ROS). These ROS react with the 
chemically covalent bonds, bridging the amino acid groups of collagen 
fibrils in a Type II photochemical reaction (4).  
 The procedure increases corneal rigidity by 328.9% (Wollensak et 
al., 2003)5. This is because of an increase in the diameter of the collagen 
fibrils mainly due to inter-fibrillar and intra-fibrillar covalent bond 
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formation, finally resulting in a more compact and strong cornea which is 
resistant to deformation and ectasia.  
 Current indications of C3R include progressive keratoconus, 
pellucid marginal degeneration and iatrogenic post refractive or post-
LASIK ectasia. Even though it slows the progression of keratoconus, it 
cannot be used in corneas thinner than 400 microns to prevent damage to 
endothelium and the deeper structures of eye (Spoerl et al., 2007)6; and 
also in previously scarred corneas. 
 Advantages of C3R include the halt in progression of the ectasia (2,4), 
which is not provided by any other modality. It is also simple to perform, 
easier to learn and requires a shorter rehabilitation period than other 
therapeutic modalities. The important point is that C3R, being a totally 
extraocular procedure, is devoid of all the complications associated with 
other procedures such as keratoplasty. 
 A putative ‘con’ of this procedure is its durability is unknown; also, 
it may have to be repeated (rarely) to treat a recurrent ectatic condition. 
Mild stromal haze is seen in a few patients which resolves within a few 
months. The major drawback of this procedure is that it cannot be used in 
extremely thin corneas (less than 400 micron thick) and corneas that have 
been scarred as a sequel to acute hydrops. Hypotonic riboflavin can be 
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used in corneas  less than 400 micron thick to swell the stroma; C3R can 
be performed after pachymetry if a value of  greater than 400 microns is 
achieved after hypotonic riboflavin. (Hafezi F et al., 2009)7 
 Various modifications of the basic procedure have been described. 
They include the original Seiler method (2,4), Caporossi’s technique(8), 
Kanellopolus intralase technique(9), Sanchez Leon modified method in 
post-LASIK ectasia, phototherapeutic keratectomy(PTK) cross-linking and 
also simultaneous topography guided photo refractive keratectomy (PRK) 
and cross-linking. 
 Complications associated with this technique have been few and 
infrequently reported. They include formation of opaque patches over time 
at the stromal level; occurrence of infection due to epithelial scraping or 
the use of contaminated riboflavin solution or bandage contact lens (BCL) 
induced infection; corneal endothelial toxicity secondary to the use of high 
fluence riboflavin or high fluence of the UV-A light especially in thinner 
corneas. The last complication can be easily avoided by proper calculation 
of the intensity of UV light and adequate saturation of riboflavin drops in 
corneal stroma which can be seen on slit lamp examination (yellow flare in 
anterior chamber under the blue filter). Riboflavin prevents UV-A 
absorption beyond 300 microns and it reduces the chance of endothelial 
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damage and potential recurrence of corneal ectasia. A new group of 
complications has emerged after the introduction of   combined use of C3R 
and PRK; these include persistent epithelial defect and permanent scarring 
of the cornea. 
 C3R is a new technique and it is being tried in various corneal 
pathologies, alone as well as in combination with other modalities. Apart 
from the current indications, which have been previously mentioned 
above, C3R is now also being used in combination with intra stromal 
corneal ring segments (INTACS) for treatment of severe keratoconus. It is 
also being done before PRK and to delay the time of corneal 
transplantation. 
 The other pathologies for which C3R has been tried and is under 
research include severe corneal edema, pseudophakic bullous keratopathy, 
corneal melting and recalcitrant infections causing corneal ulceration. To 
avoid infection, a new “no touch technique” using excimer laser episcrape 
is being used, instead of manual debridement of the epithelium. 
 Overall C3R is a simple, safe and effective new technique which is 
attracting a lot of attention in the treatment of corneal ectasia and also is 
under study for treatment of various other corneal pathologies. The 
benefits of this technique clearly outweigh the drawbacks and C3R may 
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emerge as the standard treatment modality for corneal ectatic disorders 
especially progressive keratoconus. 
 Hitherto, the most successful modality of treating early and 
moderate  cases of keratoconus  have been gas-permeable contact lenses, 
as they have the ability to correct irregular astigmatism of relatively higher 
levels, with substantial improvement in visual acuity.(Romero-Jimenez et 
al., 2013)10.When this option is not available, about 12% of individuals 
with keratoconus require penetrating keratoplasty surgery. (Gorden et al., 
2006)11. 
 More recently, C3R has been developed and used to treat 
keratoconus (Wollensak et al., Caporossi et al.)2,8. However, these studies 
were done on small number of patients, and the duration of the condition 
was variable.  
 Hence, in the current investigation, an attempt has been made to 
study the efficacy of corneal collagen cross-linking in patients with 
progressive keratoconus in the Indian population.  
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AIM OF THE STUDY 
a)  To evaluate the efficacy of corneal collagen cross-linking with 
riboflavin (C3R) in keratoconus by studying outcome in terms of 
uncorrected and best corrected visual acuity; spherical equivalent, 
cylinder value, and corneal topography. 
b)  To assess the role of C3R in preventing the progression of 
keratoconus. 
c)  To assess the safety of C3R by noting the frequency, severity and 
types of adverse events occurring during and after the procedure. 
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REVIEW OF LITERATURE 
 Keratoconus is a bilateral, non-inflammatory corneal disorder that 
leads to steepening of the inferior paracentral cornea with irregular 
astigmatism. (Krachmer JH et al., 1984)12.These patients present with 
complaints of decreased visual acuity, glare, and photophobia.  
 Clinical signs of keratoconus include Munson’s sign (protrusion of 
the lower lid on downward gaze); and Rizzuti’s sign (conical reflection of 
the nasal cornea when light is shone temporally). Slit-lamp examination of 
corneas of these patients shows inferior paracentral corneal thinning, 
presence of an ectatic cone, inferior corneal steepening, vertical stress lines 
in the posterior stroma (Vogt’s striae), iron deposition in the basal 
epithelium (Fleischer ring), and linear scar as a result of break in the 
Bowman’s layer.  
 Retinoscopy of eyes with keratoconus reveals a scissoring reflex 
and the presence of Charleaux oil reflex (bright reflex from the conical 
area surrounded by a dark circular shadow produced by the ectasia.) 
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  The pathology of keratoconus include three basic mechanisms, 
namely thinning of the stroma, breaks in the Bowman’s membrane and 
iron deposition in the basal layer of epithelium.  
 Physiologically, in keratoconus, there is a reduction in the corneal 
hysteresis (that is cornea is less capable of absorbing energy) and also the 
corneal resistance factor (that is corneal rigidity is lowered) (Ortiz D et al., 
2007).13 
 Corneal ectasia is difficult to detect clinically, especially in early 
stages. Pachymetry is useful for detection of keratoconus since it shows the 
relationship of the apical, central and thinnest part of the cornea. A 
diagnostic tool for corneal ectasia is topography. 
 Corneal topography provides useful and accurate information with 
regards to the position of the ectasia; it also permits detection of 
progression and is helpful in detection of early cases. The posterior corneal 
shape is used mainly for early recognition of this pathologic condition.  
  On topography, keratoconus can present either as a central 
symmetric but lopsided or “lazy eight” bow tie with skewed radial axes or 
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as an asymmetric bow tie with or without skewing. (Rabinowitz and 
Rasheed.,1999)14.  
 Rabinowitz has suggested diagnosis on the basis of presence of 
keratometry of more than 47.20 D, steepening of inferior cornea as 
compared with superior cornea of more than 1.2 D, skewing of radial axis 
of astigmatism by more than 21 degree. (Rabinowitz YS et al.,1995)15. 
 An important characteristic of keratoconus is that its progression is 
uneven between the two eyes. In familial keratoconus, a ‘J’ pattern or an 
‘inverted  J’ pattern may be noted. (Levy et al.,2004)16. 
 To differentiate early ectatic changes or “forme-fruste” changes 
from more stable forms, Maeda et al., (1997) 17 demonstrated a method of 
classifying corneal maps; this method was found to be more sensitive and 
specific than looking for elevated Sim-K readings and infero-superior 
asymmetry (I-S) values.  
 There are several commercially available instruments which may 
serve a diagnostic and prognostic role in corneal ectasia. The Magellan 
Mapper ™ (Nidek, Gamagori, Japan) features a  software that detects 
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various corneal diseases by using a neural network application.(Klyce D et 
al., 2005)18 
 The Orbscan™ corneal topography system (Bausch and Lomb, 
Rochester, NY, USA) uses a placido device to determine the corneal 
curvature. It takes 40 slit sections of the cornea during two scans, and the 
anterior and posterior corneal height profiles are reconstructed from these 
sections. This system provides accurate information regarding the 
morphology and topographic changes related to keratoconus. This system 
is able to suggest a risk for ectasia if there is, a variance of more than 
1.00D in astigmatism between two eyes, keratometric or corneal steepness 
on the mean power map, or  irregularity at 3 mm to 5 mm of the central 
cornea; a risk for ectasia is also suggested if the posterior surface float is 
greater than 0.05 mm or if the thinnest area of corneal thickness is more 
than 20 microns thinner than the thickness of the central cornea; two 
abnormal maps may indicate early keratoconus or corneal 
ectasia.(Karpecki et al., 2006)19 
 The Pentacam™ (Oculus, Wetzlar, Germany) is a rotating 
Scheimpflug camera with a higher depth of focus. This instrument assesses 
the anterior chamber of the eye, the topographic corneal thickness, corneal 
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curvature, anterior chamber angle and volume and height upto 25, 000 true 
elevation points. When using this instrument, anterior elevation differences 
less than  +12 microns are considered normal, anterior elevation 
differences greater than +15 microns are considered indicative of 
keratoconus, and anterior elevation differences between +12 to +15 
microns are considered suspicious. Similar figures, upto +5 microns 
higher, indicate posterior elevation. (Maus M et al., 2006)20 
 The Galilei ™ dual Scheimpflug analyser (Ziemer Ophthalmic 
systems AG, Port, Switzerland) is an instrument that, has a placido disc 
function; this instrument combines the slit and the placido data in 
displaying corneal topography.( Klyce D et al., 2009)21 
 The Reichert Ocular Response Analyzer™ (Reichert Inc, Depew, 
NY, USA) provides measurement of corneal hysteresis (CH) and the 
corneal resistance factor (CRF). It can also provide a repeatable, 
Goldmann tonometer-correlated intraocular pressure measurement. It is 
believed that CH and CRF might be useful as diagnostic tools for 
determining who might be at risk for developing post-refractive ectasia 
(Kirwan et al., 2008)22; (Ortiz D et al., 2007)13. 
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 Maeda et al., (2002)23 suggested that wavefront aberrometers may 
provide additional clues for the detection of early corneal ectasia; an 
increase in the total higher order aberrations was noted in keratoconus and 
was attributed to the corneal shape. Coma like aberrations were common in 
keratoconus eyes. 
 Therapeutic options currently available for ectatic disorders include 
the use of rigid contact lenses, specialized contact lens, INTACS,  
cross-linking with riboflavin, and lamellar or penetrating keratoplasty. 
 Cross-linking is a method that is widely used in the polymer 
industry to harden materials, and also in bioengineering to stabilize tissues. 
The most extensively studied and frequently used method as far as the 
cornea is concerned is UV-A/riboflavin collagen cross-linking. This 
method utilizes UV-A at 370 nm to activate riboflavin which is excited to 
a triplet state. This further generates reactive oxygen species (ROS), which 
induce inter-fibrillar and intra-fibrillar covalent bonds in the stromal 
collagen (4). 
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  In animal studies, collagen cross-linking with riboflavin/UV-A 
treatment has been found to induce a significant increase in corneal rigidity 
by approximately 70% (5). 
  In humans, ultraviolet cross-linking treatment appears to be able to 
halt progression of corneal ectasia in keratoconus and other condition (2 ). 
This effect of halting or even reversing the progression of the ectasia is the 
major advantage of C3R over other treatment modalities of treatment of 
corneal ectasias. 
  Cross-linking brings about biomechanical, thermochemical, 
morphological and biochemical effects, and also exhibits effects on 
keratocytes, collagenase existence and hydration behaviour in the cornea. 
 The tensile strength of the cornea is decreased in keratoconus. 
Biomechanical stress strain measurements in human corneas showed an 
increase in corneal rigidity of 328.9% and an increase in Young’s modulus 
by the factor of 4.5 after cross linking(5). The cross-linking effect is 
maximal in the anterior 300 microns of the cornea(5).  
 The maximal hydrothermal shrinkage temperature was found to be 
75 degree for cross linked porcine corneas and 70 degree for untreated 
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controls; this effect is more pronounced in the anterior stroma of the 
cornea (Spoerl E et al., 2004)24.  
 Following cross-linking, the collagen fiber diameter was found to be 
increased by 12.2% in the anterior stroma and by 4.6% in the posterior 
stroma in rabbit eyes; this was hypothesised to be because of the induced 
cross-links, pushing the collagen polypeptide chains apart, resulting in 
increased intermolecular spacing. An increase in collagen fiber diameter 
and corneal rigidity due to collagen cross-linking   has also been observed 
in diabetes mellitus and aging. (Wollensak et al., 2004)25. 
 Cross-linking was found to increase resistance against collagenase 
digestion in porcine eyes; this effect being stronger in the anterior part of 
the cornea. Such increased resistance to collagenase digestion possibly 
plays an important role in ameliorating keratoconus, since collagenase 
activity is increased in keratoconus. In the tear samples from keratoconus 
patients, collagenase metabolites were found to be 2.5 times higher than 
those in normals. (Spoerl et al., 2004)26. 
  Gel electrophoresis of cross-linked porcine corneas, revealed an 
additional intensely staining polymer band in the stacking gel that was 
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resistant to mercaptoethanol, heat and pepsin treatment. The presence of 
this polymer band is consistent with the morphologic correlate of an 
increased fiber diameter after cross-linking treatment. The chemical 
stability of cross-linked corneal fibers supports the hopes of a long-term 
effect of the new treatment.(Wollensak et al., 2008)27. 
 When cross-linked porcine eyes were examined by biomicroscopy, 
optical coherence tomography (OCT) and light microscopy, a lower degree 
of edema was found in the anterior stroma, confirming previous findings 
that the cross-linking effect is strongest in the anterior part of the corneal 
stroma. However, cross-linked corneas did not induce a specific signal on 
OCT, suggesting that OCT is not suitable as a method of clinical control of 
the cross-linking effect. (Wollensak et al., 2007)28. 
  Cross-linking has also been found to cause keratocyte apoptosis on 
anterior corneal stroma of rabbit eyes. Keratocyte apoptosis is sometimes 
reflected clinically by a transient mild corneal edema.  
 Heidelberg Retinal Tomograph II ™(Heidelberg, Germany) in vivo 
confocal microscopy in human eyes with keratoconus also showed 
rarefaction of keratocytes in the anterior and intermediate stroma 
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associated with stromal edema (spongy or honeycomb-like) immediately 
after cross-linking treatment. Three months after cross-linking, keratocyte 
re-population and disappearance of edema was observed. Six months after 
the cross-linking, keratocyte  re-population was complete.(Mazotta et al., 
2007)29.  
 Keratocyte apoptosis is not only observed after cross-linking but also 
in corneal abrasions, herpes virus keratitis and keratoconus and following 
procedures such as photorefractive keratectomy, LASIK and 
Epikeratophakia.(Wollensak et al., 2004)30. 
 Wollensak et al. (2003) 2 are credited with the first clinical  study 
that showed that corneal cross-linking (exposure to UV-A light at 
3.0mW/cm2 and riboflavin 0.1% for 30 minutes) was able to stop 
progressive keratoconus in all 23 eyes of 22 patients; these patients ranged 
from 13 to 58 years in age with the average age being 34.7 ± 11.9 years. 
Steep keratometry values reduced from 2.01 Diopters in 70% of the eyes 
with a refractive correction of 1.14 diopters. Over an average follow-up 
time of 23 months, no scarring in the cornea, no lenticular opacities and no 
endothelial cell loss was seen, while intraocular pressure did not change 
after the procedure. 
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 In a subsequent study, these authors found that C3R is able to 
stabilize the cornea in keratoconus and may diminish the need for corneal 
transplant (4). 
 Five year follow-up results to this pioneering study have been 
published in a subsequent  review of cross-linking by Wollensak (4). In 150 
eyes treated, 60 eyes had a 5-year follow-up and no progression of 
keratoconus was seen in any of these patients. In 31 eyes (52%), a 
reduction in keratometry of 2.87 diopters was seen with best spectacle 
corrected visual acuity (BSCVA) improving by 1.4 lines.  
 Caporossi et al. (2006)8 in their prospective study conducted in 10 
eyes with bilateral keratoconus in Italy reported reduction in mean 
keratometry   reading  confirmed by topography, and improvement in 
visual acuity following  C3R.  
 These authors also conducted a long term trial in Italy, widely 
known as the Siena Eye Cross Study on 363 eyes with progressive 
keratoconus with a mean follow-up of 52.4 months found long term 
stability of keratoconus with improvement of visual acuity and no side 
effects. (Caporossi et al., 2010)31 
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 Raiskup-Wolf et al. (2008)32 following their long-term study on 480 
eyes of 272 individuals with keratoconus in Germany, concluded that there 
is a long-term stabilization and improvement after collagen cross-linking; 
they thus felt that collagen cross-linking is an effective therapeutical option 
for progressive keratoconus. 
 Goldich et al. (2012)33 in  Israel reported  visual acuity improvement 
and stabilisation of keratoconus at two years following C3R, in their 
prospective study on fourteen patients. They also observed no change in 
corneal thickness, endothelial cell density and foveal thickness suggesting 
the safety of this procedure. 
 In a prospective comparative study on 55 eyes of 39 patients by 
Muriel et al.(2013)34 in France, showed stabilisation of  keratoconus with 
no side effects, at the end of  three year  following C3R. 
 Viswanathan et al. (2013)35, concluded that corneal collagen  
cross-linking using riboflavin and ultraviolet-A is effective as a therapeutic 
option in cases of progressive keratoconus by reducing the corneal 
curvature and improving the visual acuity in these patients; their study was 
performed in 35 patients. 
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 Vinay Agrawal et al.(2009)36 in their retrospective analysis of effect 
of C3R on 37 Indian eyes with one year follow-up  reported reduction in 
the K value in 66% of eyes by a mean of 2.73D and in 22% of the eyes it 
remained stable. Thus they suggested C3R as an effective treatment  for 
progressive keratoconus. 
 In another retrospective study of 28 eyes with advanced keratoconus 
with maximum K value of more than 55D preoperatively showed 
improvement in 27 eyes following C3R at last visit. Thus they concluded 
C3R helps in preserving visual acuity and delaying keratoplasty in patients 
with advanced progressive keratoconus. (Ivarsen et al., 2013)37 
 The Sienna CXL Paediatrics study in 152 patients less than 18 years 
of age observed rapid and stable functional recovery in terms of UCVA, 
BCVA and coma values in 80% of the cases without any complications. 
Hence they suggested the elective use of C3R for treating progressive 
keratocnus in paediatric population. (Caporossi et al., 2012)38 
  Lamy et al. (2013)39 in  Brazil  showed improvement in contrast 
sensitivity in all 68 eyes with progressive keratoconus treated with C3R at 
the end  of two years. 
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 Hafezi et al. (2009)7 in a study on 20 individuals in Switzerland, 
concluded that the preoperative swelling of the cornea safely broadens the 
spectrum of C3R indications to thin corneas that would otherwise not be 
eligible for treatment. 
 Caporossi et al.(2012)40 in 10 patients noted that  in vivo confocal 
analysis of corneal modifications induced by trans-epithelial corneal 
collagen cross-linking (TE C3R) showed a limited apoptotic effect of this 
treatment, about one-third of classic epi-off crosslinking procedure. The 
TE C3R respected sub-basal and anterior stroma nerve fibers, and was thus 
safe for corneal endothelium.  
 Caporrosi et al.(2013)41  in a prospective study, reported unstable 
functional recovery in 26 patients after trans-epithelial CXL. Re-treatment 
was required in 50% of these patients with epi-off  CXL. 
 C3R has gained mass appeal and is likely to become the standard 
treatment modality for early and moderately advanced progressive 
keratoconus. However, individuals with stromal scarring, corneal thickness 
of less than 400 microns at the thinnest point are poor candidates for C3R. 
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 C3R is also a viable option in progressive post-LASIK keratectasia, 
which hitherto, had the only option of a custom designed contact lens or a 
corneal transplantation. Here also a minimum thickness of 400 microns in 
the thinnest point of the cornea is a limiting factor. The process of swelling 
the cornea to 400 microns and then harnessing C3R is the way to proceed. 
The hypoosmolar solution of 0.5% Riboflavin (diluted in BSS in a 1:4 
concentration) is applied till the cornea swells to a thickness of 400 
microns. Also one should not swell a keratoconic cornea more than 80 
microns as these corneas have a different swelling pattern. 
 Crosslinking has shown favorable outcomes in eyes with pellucid 
marginal degeneration. However, a larger 11 mm area should be exposed 
as of against the usual 9 mm advocated. A merocoel protection ring is 
advised to protect the limbal stem cells and also an eccentric corneal light 
exposure is advised. 
 Nowdays, C3R is being combined with intrastromal corneal ring 
segments (INTACS) in an attempt to flatten the cornea. However it does 
not solve the problem of weakening of collagen. INTACS acts as an 
additive measure to flatten the cornea. Another mechanism proposed is 
24 
that, INTACS cause pooling of the riboflavin in the area of its segment 
which has the maximum cross-linking effect. 
 Coskunseven et al. (2009)42 in a study on individuals with 
keratoconus in  Turkey, observed that implantation of ICRS followed by 
C3R resulted in greater improvement of keratoconus. 
 Kilic et al. (2012)43 in Turkey, observed that combined ICRS and 
C3R treatment with intracorneal riboflavin injection was effective in 131 
keratoconic eyes. Intracorneal riboflavin injection into the tunnel was safe. 
The authors felt that intracorneal riboflavin injection might provide more 
penetration without epithelial removal. 
 The pre-treatment of corneas with C3R before PRK by a couple of 
months is a possible detour, it gives a window period of better visual 
acuity till the eventual corneal transplant is planned. 
 C3R treatment improves cross-linking and tightens the peripheral 
incisions of the radial keratotomy (RK) which leads to a more stable 
cornea. This halts the progressive flattening and the induced hyperopia 
post-RK. 
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 Other applications of C3R are being studied in cases of 
pseudophakic bullous keratopathy where the corneas need to be initially 
deswelled using glycerol till they achieve a thickness of 400 microns. In 
cases of corneal melting, a lower surface irradiation (2.5 mw / cm2) is 
given to compensate for a thinner cornea. Here, the cross-linking increases 
the cornea’s resistance to digestive enzymes such as collagenase which 
cause the melting.  
 Ghanem et al.(2010)44 in a study on 14 individuals with 
pseudophakic bullous keratopathy (PBK), in Brazil, noted that corneal 
C3R significantly improved corneal transparency, corneal thickness, and 
ocular pain, one month post-operatively. However, it did not seem to have 
a long-lasting effect in decreasing pain and maintaining corneal 
transparency in patients with PBK. 
 Recently, C3R has been tried for treating recalcitrant infectious 
keratitis. Moren et al.(2010)45 in a study on a patient with presumed 
infectious keratitis in Sweden, observed the positive effects of riboflavin 
and UV-A collagen cross-linking with a satisfactory final visual outcome. 
Although these authors felt that this might be a promising new treatment 
for keratitis, they believed that this treatment should only be considered in 
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therapy-refractive keratitis or ulceration and not in the first line of defence, 
since it might have cytotoxic side effects. 
 Photoactivated  riboflavin therapy was performed in seven eyes with 
refractory infectious keratitis in a study by Panda et al.(2013)46.They 
observed cessation of corneal melting in all cases following treatment. 
 Despite the advantages of C3R, fewer complications have been 
reported in the literature. Wasilewski D et al. (2013)47 in  Brazil, reported 
that corneal cross-linking performed in 36 keratoconus patients induced a 
considerable decrease in corneal sensitivity; this decrease was more 
intense at the first week after the procedure, with a progressive recovery up 
to 6 months. 
 Bhupesh Bagga et al. (2012)48 reported a case of 
histopathologically  proven endothelial decompensation  following C3R, 
requiring keratoplasty.  
 Sharma et al.(2010) 49 reported a case of pseudomonal keratitis in a 
19 year old woman who underwent C3R and this was attributed to the use 
of bandage contact lens in the early post-op period. 
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MATERIALS AND METHODS 
 The current investigation was a prospective interventional study on 
patients with keratoconus who presented to the Cornea Clinic, Institute of 
Ophthalmology, Joseph Eye Hospital, Tiruchirapalli, Tamilnadu over a 20 
month period (April 2011 to November 2012). This study was approved by 
the Institutional Ethics Committee. 
 Fifty eyes were included in this study. The study was done to assess 
the efficacy of C3R in keratoconus and its role in preventing the 
progression. 
 Patients were enrolled   in   the study if they provided informed 
written consent to participate, and if they fulfilled the following criteria. 
(Inclusion criteria) 
a)  presented with progressive keratoconus for which they had  not 
undergone any other surgical modalities of treatment. 
b)  keratoconus with an average K value not exceeding 60 D and were 
less than 25 years of age. 
c)  had a central corneal thickness of more than 400 microns at the 
thinnest point; and 
d)  did not exhibit sub-epithelial and stromal scarring on slit lamp 
biomicroscopic examination. 
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 Patients were not considered for the study (exclusion criteria) if any 
one of the following was present:  
a)  patient was more than 25 years old; 
b)  central corneal thickness was less than 400 microns at the thinnest 
point; 
c)  stationary keratoconus, a scarred cornea or acute hydrops was 
present; 
d)  patient was pregnant or lactating; 
e)  patient suffered from an autoimmune disease or diabetes mellitus; or 
f)  patient had an active ocular infection. 
 The main outcome measures evaluated included determination of 
uncorrected and best corrected visual acuity, spherical equivalent, cylinder 
value, and corneal topography, before and after C3R, and the frequency, 
severity and types of adverse effects, if any, following C3R. 
 Measurements were made at baseline (before the treatment) and at 
follow-up visits at one month, six months and one year after treatment.  
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PROCEDURE: 
 Each patient was informed of the procedure and its possible 
complications and written informed consent was obtained; the Institutional 
Ethics Committee approved the study. 
 The procedure was performed in operating room under sterile 
conditions. Topical proparacaine hydrochloride (0.5%) eye drops was 
instilled before the procedure. The central corneal epithelium (9 mm) was 
then debrided mechanically with a blunt Hockey knife to allow better 
penetration of riboflavin. This was followed by the application of 
photosensitizer riboflavin (0.1% solution) to the de-epithelialised cornea 
every two minutes for a period of approximately 30 minutes. To confirm 
adequate penetration had occurred, a yellow anterior chamber flare under 
blue filter was looked for by slit lamp examination.  
 Exposure to UV-A light was initiated only after ensuring that 
adequate penetration of riboflavin had occurred, as indicated by the 
presence of a yellow flare in the anterior chamber. The cornea was then 
subjected for the next 30 minutes to UV-A radiation (370 nm), in a  dose 
of  3mW/Sq.cm, by an irradiating source placed at a distance of 5 cm from 
the center of the cornea. To complete photosensitisation and to provide 
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photoprotection by a barrier effect, riboflavin (0.1% drops) were again 
instilled every two minutes during the irradiation treatment. 
 On completion of the procedure, the patient received topical 
ofloxacin and flurbiprofen eye drops following which a sterile bandage 
contact lens is applied for three days or till the   re-epithelisation of cornea.  
 Post-procedure, the patient was prescribed topical ofloxacin drops 
four times a day along with flurbiprofen eye drops four times a day for 
three days till epithelium healed. Once the epithelium had healed 
completely, topical prednisolone drops were initiated starting at four times 
a day and gradually tapering the frequency of application over a month 
period. Topical lubricating eye drops were also applied four times a day 
for six months. 
  
Fig. 1 Clinical photo of an eye with keratoconus showing Vogt’s striae 
 
 
 
 
Fig 2 : Clinical photo of an eye with keratoconus showing prominent 
corneal nerves 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig 3: UV-X ™ instrument used for performing C3R 
 
 
  
  
Fig 4: Step1: Measurement of corneal diameter for epithelial 
debridement 
 
 
Fig 5: Step 2: Mechanical debridement of corneal epithelium 
 
 
  
Fig 6: Step 3: Instillation of riboflavin (0.1%) drops every two minutes 
for 30 minutes 
 
 
 
Fig 7: Step 4: Exposure to UV-A (370 nm) with sequential 
administration of riboflavin (0.1%) drops every two minutes for the 
next 30 minutes. 
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RESULTS 
 The present investigation was a prospective, interventional study on 
patients who presented with various grades of keratoconus at the Cornea 
clinic, Joseph Eye hospital, Trichy, over a period of 26 months. (April 
2011 to April 2013). Patients were enrolled between April 2011 to 
November 2012, follow-up was over a period of 6 to 12 months, and data 
were analysed subsequently.  
 Sixty individuals with features of keratoconus were seen during the 
enrolment period. Of these, 22 individuals had at least one exclusion 
criterion or declined to participate in the study. Finally, 38 patients (50 
eyes) who satisfied the inclusion criteria and who consented to undergo 
corneal collagen cross-linking with riboflavin (C3R) were enrolled in the 
study. 
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1)  DEMOGRAPHIC ASPECTS 
1.1)  Gender and Age Distribution: 
 Fifty eyes of 38 patients were included in this study. There were 20 
males (53%) and 18 females (47%). (Chart.1). The mean age of the 
patients was 19.2 ± 4.5 years (range 11-25 years). There were 12 (31.5%) 
patients aged between 10-15 years, 11 (28.9%) between 16-20 years and 
15 (39.5%) between 21 -25 years. (Chart 2). 
Chart 1: Gender distribution of patients with keratoconus 
undergoing corneal collagen cross-linking at a tertiary eye 
care hospital  
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Chart 2:  Age distribution of patients with keratoconus undergoing 
corneal collagen cross-linking at a tertiary eye care 
hospital 
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1.2)  Laterality of the eye undergoing corneal collagen cross-linking 
with riboflavin: 
 Twenty six patients (68%) underwent C3R in one eye and 12 
patients (32%) in both eyes with the severe eye treated first. (Chart. 3) 
 
Chart 3:  Laterality of the eye with keratoconus undergoing corneal 
collagen cross-linking at a tertiary eye care hospital: 
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1.3)  Indications for corneal collagen cross-linking with riboflavin 
 Sixteen eyes (32%) had stage I keratoconus, 23 (46%) eyes had 
stage II keratoconus, and 11 eyes (22%) had stage III keratoconus, based 
on the Krumeich classification (50). 
2)  CHANGES IN VISUAL ACUITY: 
2.1)  Changes in uncorrected visual acuity (UCVA): 
 The mean UCVA before treatment was 0.18 ± 0.16 (in decimals) 
(6/60-6/36), and the mean UCVA at the end of one month after C3R was 
0.20 ± 0.17(6/36); this improvement was statistically significant (p=0.05) 
(Table1). The visual acuity continued to improve at 6 months (0.26 ± 0.19 
(6/24); p <0.0001) and at one year of follow up (0.32 ± 0.22(6/18),  
(p <0.0001).Thus there was statistically significant improvement in mean 
UCVA at all visits post-C3R (Table 1). 
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Table 1:  Comparison of uncorrected visual acuity in eyes with 
keratoconus undergoing corneal collagen cross-linking 
with riboflavin at a tertiary eye care hospital: 
Examination time Uncorrected visual acuity 
Mean ± SD (decimals) 
*p-value 
Baseline 0.18 ± 0.16 - 
1month 0.20 ± 0.17 0.050 
6month 0.26 ± 0.19 <0.0001 
1year 0.32 ± 0.22 <0.0001 
*Note: Paired student ‘t’-test applied. 
SD – Standard deviation. 
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Chart 4 :  Comparison of uncorrected visual acuity (UCVA) among 
study group 
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2.2)  Changes in best corrected visual acuity (BCVA): 
 The mean BCVA pre-treatment was 0.51 ± 0.27(6/12), and post-
C3R (one month) it was 0.52 ± 0.25(6/12); p= 0.66), this improvement was 
not of statistical significance (Table 2). However, BCVA showed 
statistically significant improvement at six months (0.63 ± 0.25(6/12-6/9), 
(p<0.0001), and at one year (0.76 ± 0.22(6/9-6/6); p <0.0001),   
post-treatment compared with the pre-treatment data, reaching its 
maximum at one year with mean BCVA of 0.76 ± 0.22 (in decimals) (6/9-
6/6), (p <0.0001) (Table 2). 
Table 2:  Comparison of best corrected visual acuity in eyes with 
keratoconus undergoing corneal collagen cross-linking 
with riboflavin at a tertiary eye care hospital: 
Examination time Best corrected visual 
acuity Mean ± SD 
(decimals) 
*p-value  
Baseline 0.51 ± 0.27 - 
1month 0.52 ± 0.25 0.664 
6month 0.63 ± 0.25 <0.0001 
1year 0.76 ± 0.22 <0.0001 
*Note: Paired student ‘t’-test applied. 
SD – Standard deviation. 
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Chart 5 : Comparison of BCVA among study group 
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3)  CHANGES IN SPHERICAL EQUIVALENT AND CYLINDER 
VALUE : 
3.1)  Changes in the Spherical equivalent (SE) 
 The baseline mean SE was -4.60 D (SD ± 2.99), (Table 3). The 
mean SE was found to have reduced to -4.45 D (SD ± 2.85) at one month 
following C3R; however this reduction was not statistically significant  
(p = 0.35). Further reduction in SE value compared to baseline mean SE 
was noted at the end of 6 months ( -3.97 D (SD ± 2.60); p = 0.001); and at 
one year (-3.63 D (SD ± 2.70); p = 0.001) (Table 3). Thus the mean SE 
decreased during the follow up period, with the difference from the 
baseline reaching statistical significance at 6 months and one year.  
(p = 0.001) (Table 3). 
Table 3:  Comparison of spherical equivalent in eyes with 
keratoconus undergoing corneal collagen cross-linking 
with riboflavin at a tertiary eye care hospital: 
Examination time Spherical equivalent  
 Mean ± SD (diopters) 
*p-value 
Baseline -4.60 ± 2.99 - 
1month -4.45 ± 2.85 0.358 
6month -3.97 ± 2.60 0.001 
1year -3.63 ± 2.70 0.001 
*Note: Paired student ‘t’- test applied. 
SD – Standard deviation 
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Chart 6  :  Comparison of Spherical equivalent (SE) among study 
group 
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3.2)  Changes in the Cylinder value: 
 The mean cylinder value at baseline was -3.70 D (SD ± 1.86), and 
reduction in the cylinder value throughout the one year follow-up period 
was observed post-treatment (Table 4). The mean cylinder value at the end 
of one month was -3.18 D (SD ± 1.4); p=0.01), at 6 months was -2.71D 
(SD ± 1.52); p<0.0001); and at one year was -2.39 D (SD ± 1.40), 
(p<0.0001) (Table 4). 
 This reduction in mean cylinder value from baseline throughout the 
follow-up at one month, 6 months and  at one year  post- C3R was found 
to be statistically significant at all post-operative visits (p<0.0001)  
(Table 4). 
Table 4:  Comparison of cylinder value in eyes with keratoconus 
undergoing corneal collagen cross-linking with riboflavin 
at a tertiary eye care hospital: 
Examination time Cylinder value 
 Mean ± SD (diopters) 
*p-value 
Baseline -3.70 ± 1.86 - 
1month -3.18 ± 1.4 0.013 
6month -2.71 ± 1.52 <0.0001 
1year -2.39 ± 1.40 <0.0001 
*Note: Paired student ‘t’-test applied. 
SD – Standard deviation. 
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Chart 7:  Comparison of cylinder value among study group 
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4)  CHANGES IN KERATOMETRY READINGS: 
4.1)  Changes in keratometry value of steeper meridian (Kmax): 
 The mean keratometry value of the steeper meridian (Kmax) at 
baseline was 53.49 D (SD ± 4.35), (range: 47 - 60.25 D) (Table 5). The 
mean Kmax at one month post-treatment was found to have reduced to 
52.37 D (SD ± 8.68; p=0.001).There was further reduction at 6 months 
(51.94 D (SD ± 8.75), p <0.0001); and at one year ( 51.67 D (SD ± 8.76 );  
(p <0.0001) (Table 9). This reduction in the Kmax value from baseline was 
statistically significant at all post-operative visits (p <0.0001). 
 The quantum of reduction in the mean K max value compared to the 
baseline was 0.14 D at one month, 0.63 D at six months and was  0.90 D at 
one year (Table 5). 
Table 5:  Comparison of Kmax in eyes with keratoconus 
undergoing corneal collagen cross-linking with riboflavin 
at a tertiary eye care hospital 
Examination time Kmax 
Mean ± SD (diopters) 
*p-value 
Baseline 53.49 ± 4.35 - 
1month 52.37 ± 8.68 0.001 
6month 51.94 ± 8.75 <0.0001 
1year 51.67 ± 8.76 <0.0001 
*Note: Paired student ‘t’-test applied. 
SD – Standard deviation. 
Kmax - keratometry value of the steeper meridian. 
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Chart 8 :  Comparison of Kmax among study group 
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4.2)  Changes in keratometry value of the flatter meridian (Kmin): 
 The mean keratometry value of the flatter meridian (Kmin) was 
47.41 D (SD ± 3.50) (range: 45.12 - 56.12  D) prior to treatment (Table 6). 
At one month post-C3R, the Kmin value was 46.41 D (SD ± 7.53); 
p=0.001); and at 6 months post-C3R was 46.09 D (SD ± 7.53); p <0.0001); 
and at one year post-C3R, it was 45.91 D (SD ± 7.53); p <0.0001). This 
constant reduction in Kmin value from baseline throughout the follow-up 
period was statistically significant. (p <0.0001). 
 The quantum of reduction of the mean Kmin value was found to be 
0.11 D at one month, 0.44 D at 6months , and 0.63 D at one year  
follow-up, respectively (Table 6). 
Table 6:  Comparison of Kmin in eyes with keratoconus undergoing 
corneal collagen cross-linking with riboflavin at a tertiary 
eye care hospital: 
Examination time Kmin 
Mean ± SD (diopters) 
*p-value 
Baseline 47.41 ± 3.50 - 
1month 46.41 ± 7.53 0.001 
6month 46.09 ± 7.53 <0.0001 
1year 45.91 ± 7.53 <0.0001 
*Note: Paired student ‘t’-test applied. 
SD – Standard deviation. 
Kmin- keratometry value of the flatter meridian. 
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Chart 9:  Comparison of  Kmin among study group 
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4.3)  Changes in average  keratometry value (Kavg): 
 The mean average keratometry value (Kavg) at baseline was 50.45D 
(SD ± 3.75) (range: 47.25-57.62 D) (Table 7).There was reduction in Kavg 
value at one month post-C3R to 49.39 D (SD ± 8.03), and this reduction 
was statistically significant (p =0.002). On follow-up, the Kavg value was 
found to be further reduced to 49.01 D (SD ± 8.06), p <0.0001) at 6 
months, and to 48.79 D (SD ± 8.06), p<0.0001) at one year post-C3R 
(Table 7). This reduction in Kavg value on follow-up was of statistical 
significance. 
 This study also recorded a reduction in the mean Kavg value during 
the follow-up, by a mean of  0.12 D at one month, 0.54 D at 6 months, and 
0.77 D at one year post-C3R (Table 7). 
Table 7: Comparison of K avg in eyes with keratoconus undergoing 
corneal collagen cross-linking with riboflavin at a tertiary 
eye care hospital 
Examination time Kavg 
Mean ± SD (diopters) 
*p-value 
Baseline 50.45 ± 3.75 - 
1month 49.39 ± 8.03 0.002 
6month 49.01 ± 8.06 <0.0001 
1year 48.79 ± 8.06 <0.0001 
*Note: Normality test failed, thus Wilcoxon Signed ranks test applied. 
SD – Standard deviation. 
Kavg - mean average keratometry value. 
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Chart 10 : Comparison of Kavg among study group 
 
 
 
 
 
 
50 
5)  Patients and ocular factors affecting the response to treatment: 
 In this study, eyes that showed a reduction in Kavg value by more 
than 0.5 D from the baseline, at the end of one year follow-up were 
considered improved and those eyes which showed reduction of less than 
0.5 D were considered stable. 
 Thirty-four eyes showed improvement and 10 eyes remained stable 
at the end of one year   follow-up in this study. 
5.1)  Gender 
 In the improved group (n=34 eyes), there were 13 males and 13 
females (34 eyes of 26 patients) and in the stable group (n=10 eyes), there 
were five males and four females (10 eyes of 9 patients); this difference 
was not statistically significant.  (χ2=0.085; (d. F=1); p=0.77). 
5.2)  Age 
 In the improved group (n=34 eyes), 11 patients were aged below 20 
years and 15 patients were aged above 20 years; and in the stable group 
(n=10 eyes), four patients were aged below 20 years and five patients were 
aged above 20 years. There was no statistically significant difference with 
respect to age affecting the response to treatment.  
(χ2=0.015; (d. F=1); p=0.90). 
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5.3)  Central corneal thickness 
 There were 25 eyes (73.52%), with central corneal thickness more 
than 450 microns and nine eyes (26.48%) with central corneal thickness 
less than 450 microns in the improved group (n=34 eyes). In the stable 
group (n=10 eyes), there were eight eyes (80%) with central corneal 
thickness more than 450 microns and two eyes (20%) with central corneal 
thickness less than 450 microns; this  was of no statistical significance in 
affecting the treatment outcome.  (χ2=0.159; (d. F=1); p=0.69). 
5.4)  Average keratometry reading  
 The baseline mean K avg value was more than 50 D in 15 eyes 
(44.12%) and less than 50 D in 19 eyes (55.88%) in the improved group 
(n=34 eyes), and the baseline mean K avg value was more than 50 D in 
seven eyes (70%) and less than 50 D in three eyes (30%) in the stable 
group (n=10 eyes). There was no statistically significant difference in the 
pre-treatment Kavg value influencing the response to treatment.  
(χ2=2.072; (d. F=1); p=0.15). 
 In this study, an increase in Kavg value compared to baseline value 
by less than 0.5 D was observed in four eyes (8%), at the end of one year 
of follow-up. Further analysis was not done because of smaller size of the 
group. 
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Table 8:  Patients and ocular factors affecting the response to 
treatment 
Parameters No. of improved 
eyes (%) 
P value (Chi-square 
test) 
Gender  (Male) 
  (Female) 
13 (72.22%) 
13 (76.47%) 
0.77 
Age   (< 20 years) 
   (> 20 years) 
11 (73.33%) 
15 (75%) 
0.90 
CCT   (> 450 microns) 
   (< 450 microns) 
25 (75.75%) 
9 (81.81%) 
0.69 
Avg K  (< 50D) 
  (> 50D) 
19 (86.36%) 
15 (68.18%) 
0.15 
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6)  Complications 
  Two patients in this study developed complications in the form of 
corneal ulcer within the first month of the procedure. Both the patients 
were started on topical broad spectrum antibiotics. On further follow-up, 
one patient improved, but corneal scarring occurred with resultant 
steepening of average K values. On the other hand, in the other patient, the 
ulceration progressed necessitating   therapeutic  penetrating keratoplasty. 
Thus complications were noted in only two (4%) of 50 eyes in this study. 
  
 
 
 
 
Fig. 8: Corneal topography map of a study eye showing typical 
asymmetric bow-tie pattern of keratoconus prior to C3R 
 
  
  
 
 
 
 
Fig. 9:Corneal topography map of the same study eye showing an 
improvement in the keratometric readings post-C3R
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DISCUSSION 
 Corneal collagen cross-linking with riboflavin (C3R) is a promising 
new treatment modality for keratoconus patients as it provides various 
advantages over the conventional treatment modalities for corneal ectasia. 
The specific advantage of C3R over the other modalities is that it halts the 
progression of the disease and, in some cases, it also causes a partial 
reversal of the pre-existing ectasia, and also defers the need for 
keratoplasty. 
 The basis underlying this technique was understood only after a 
detailed study of the pathogenic mechanisms of ectatic disorders. C3R 
increases the mechanical and chemical stability of the corneal tissue by 
creating additional chemical covalent bonds in the corneal stroma by 
means of highly localized photopolymerization (4) ; this leads to either 
slowing down or total arrest of the progression of ectasia (2,4). According to 
one study, C3R increases corneal rigidity by 328.9% (5). In addition to 
keratoconus, C3R is now being sucessfully tried for the treatment of 
pellucid marginal degeneration, progressive post-LASIK keratectasia 
(PPLK), bullous keratopathy, infectious keratitis, and corneal melts. 
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 In the present study, an attempt was made to study the efficacy of 
C3R in patients with progressive keratoconus and its outcome was 
followed-up over a period of one year. The indicators which were used to 
assess the outcome of C3R were UCVA, BCVA, SE, cylindrical error, 
keratometry values ( Kmax, Kmin, Kavg), and the rate of development of 
complications if any. 
 Much research has been done on this topic in the western population 
where the procedure showed encouraging results. However, with respect to 
the Asian population, only a few studies have been done. Hence, the 
current study is of great relevance. 
Demographics: 
 In the current study, 38 patients were included of which 50 eyes 
underwent C3R. All the patients were followed up for a minimum period 
of one year. Unlike a few other studies, such as by Raiskup et al. (2008)32 
who studied 480 eyes of 272 patients, the sample size included in this 
study was relatively small.  
 The ratio of male: female  patients in the current study was 1:1 
(Chart 1). A study by Caporossi et al. (2011)51 had a male: female ratio of 
4:1. In other reported literature (1), the male: female ratio was 2:1. This 
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possibly reflects the variation in the incidence of the disease in the Asian 
population, as compared to its Western counterparts. 
 Keratoconus, being a bilateral, asymmetric disease, presents with 
one eye affected more than the other in most circumstances. This is seen in 
the current study as 68% of the patients included in the study had a 
unilateral disease requiring treatment at presentation (Chart 3). 
 The mean age of patients included in this study was 19.2 ± 4.5 years 
(range 11-25 years) (Chart 2). The other related studies done in the west 
show a higher mean age of patients. In the trial done by Wollensak et al. 
(2003)2 and the one done by Caporossi et al .( 2006)8, mean age groups of 
31.7 years and 31.4 years, respectively, were reported.  
 In the study by Caporossi et al.( 2011)51, the patients were divided 
into 3 groups on basis of age. The study concluded that the benefit of the 
C3R procedure was more in the paediatric  group and in  patients below 26 
years of age.  Koller et al.(2009)52 observed  a poor outcome of the 
procedure when performed in individuals above 35 years of age. 
 A previous study done on the Indian population by Agrawal et 
al.(2009)36 included  patients with a mean age of 16.9 ± 3.5 years ( range : 
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12-39 years). This might point to the fact that the incidence of keratoconus 
may be higher in the younger age groups in the Asian population. 
 The speed of keratoconus progression in paediatric age group as 
compared to adult keratoconus is higher as proven in many studies. Chatzis 
and Hafezi et al. (2012)53 found that 88% of keratoconic patients in the 
paediatric age group showed a progression from their initial evaluation. 
Soeters et al., (2011)54 noted progression of keratoconus to be rapid in 
paediatric patients, which  ranged from 2.6 D in seven weeks to 5.0 D over 
a period of one year. These observation suggest that treatment at 
presentation of disease may be initiated as opposed to waiting for signs of 
progression.  
 However, the present study did not observe any impact of the age 
parameter on visual and topographic outcome after C3R (Table 8). Thus 
the importance of doing C3R during the early course of disease is 
highlighted especially in the Asian population in whom the age of 
presentation of keratoconus was found to be younger. This might delay or 
eliminate the need to perform more invasive surgeries such as lamellar or 
penetrating   keratoplasty. 
 In the current study, the patients included were staged by the 
Krumeich classification (50) with the maximum percentage falling in  
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stage II keratoconus. This study did not attempt to infer any positive or 
negative impact on the outcome parameters based on these criteria. 
However, in a study by Koller et al.(2009)52, an observation was made that 
a poor post-operative prognosis was seen if C3R was done in patients 
having a high keratometry value of more than 58 D (stage III). 
 In the current study, pre-operatively, the central corneal thickness 
was measured by a pachymetry for all the patients enrolled in the study. 
This parameter was not measured on subsequent follow-up visits. The 
current study did not observe any influence of pre-operative corneal 
thickness in the functional outcome of the procedure (Table 8). 
 In the landmark Sienna CXL trial conducted by Caporossi et al. 
(2012)38, the patients were divided into two groups on the basis of CCT  
(< 450 and > 450 microns). It was observed that, the visual outcome in the 
form of UCVA and BCVA and also the visual recovery  were better in the 
group with thicker cornea. In a study conducted by Kankaria et al., 
(2013)55, it was observed that the CCT reduced in value at one month and 
this gradually recovered in subsequent follow up visits. In the same study, 
the authors suggested that the trans-epithelial variety of C3R may be tried 
in patients with thin corneas. Greenstein et al. (2013)56, however did not 
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find any impact of pre-operative corneal thickness on the outcome of the 
procedure, as observed in the current study. 
Uncorrected visual acuity 
 In the current study, an observation was made that the mean UCVA 
(in decimals) calculated at all post-operative follow-up visits showed a 
statistically significant improvement in comparison to the  pre-operative 
mean UCVA, improving from 0.18 to 0.32 at the final follow-up visit at 
one year (Table 1). Similar studies conducted in the west, such as one done 
by Caporossi et al. (2010)31 demonstrated a statistically significant 
improvement in terms of Snellen lines at all follow-up visits upto two 
years after the procedure. In the Sienna CXL trial conducted on paediatric 
patients, Caporossi et al.(2012)38 observed a statistically significant 
improvement in the mean UCVA. 
 Studies conducted on the Indian population showed comparable 
results which were encouraging. Arora et al. (2012)57 demonsrated   an 
improvement in UCVA at the end of one year. Thus there was a 
statistically significant improvement post the C3R procedure across all the 
studies. 
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Best corrected visual acuity 
 Concurrent to the improvement in the UCVA, the BCVA also 
showed a gradual improvement in comparison to the baseline BCVA in the 
present study (Table 2). However the improvement in comparison to the 
baseline BCVA was statistically significant only at 6 months and one year 
follow-up visits. The one month value was not found to be statistically 
significantly different from the pre-operative value. The mean BCVA 
improved from 0.51 to 0.76 at one year (Table 2). 
 A study by Caporossi et al. (2010)31 demonstrated a mean 
improvement in BCVA at all the follow-up visits until two years from the 
procedure. Raiskup et al. (2008)32 in their long term study showed an 
improvement in BCVA in terms of Log MAR value at the end of 6 years. 
In other one-year follow up studies by Witting Silva et al. ( 2008)58 and 
Hersh et al. (2011)59 also showed a Log MAR improvement similar to that 
seen in the present study. Caporossi et al. in the Sienna CXL paediatric 
trial (2012)38 observed a statistically significant improvement at final  
follow-up visit of 36 months. 
 Studies conducted in the Indian population had comparable results, 
Arora et al. (2012)57 found an improvement in mean BCVA at the end of 
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one year. In another study by Agrawal et al. (2009)36, an improvement in 
terms of Snellen lines was observed at the end of one year.  
 Thus, the procedure shows a  statistically significant improvement in 
the BCVA, irrespective of the population demographic. Also, the lack of 
statistically significant improvement in BCVA in the current study at one 
month follow-up might suggest the late stabilization of the visual and 
topographic parameters and might be indicative of the post-operative 
visual recovery and rehabilitation time, or might reflect the small sample 
size studied. 
Spherical equivalent 
 Spherical equivalent was calculated as the sum of the spherical value 
(DS) and half of the cylindrical value (1/2DC). 
 In the current study, the mean pre-operative SE value was found to 
show a gradual reduction at all the post-operative visits (Table 3). This 
reduction in the SE when compared to the pre-operative values was found 
to be statistically significant. 
 Agrawal et al. (2009)36 in a study conducted in the Indian 
population, also observed a similar reduction in the values of both the 
sphere and the SE. Another study by Vinciguerra et al. (2012)60 observed a 
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reduction  in  the  spherical equivalent value, two years after the CXL 
procedure.  
 Thus, it appears that reduction of the value of  spherical equivalent 
post-C3R occurs  in both the western and Asian patients. 
Cylinder value 
 The current study also compared the mean reduction of the 
cylindrical value in the group (Table 4). In comparison to the preoperative 
mean cylindrical value of -3.70 D, statistically significantly lower values 
were noted at all follow-up visits, and a value of -2.39 D being noted at 
the final post-operative visit at one year. 
 Studies by Caporossi et al. ( 2006)8  and Saffarian L et al. (2010)61  
demonstrated a similar reduction  in cylindrical value which might be 
indicative of gradual corneal flattening post-C3R. 
Keratometric readings 
 The topographic indices, such as the Kmax (the steeper meridian), 
Kmin (the  flatter meridian) and the  Kavg (average keratometry) values 
over each of the follow-up visits at one month, 6 months and one year 
were observed in the present study (Table 5, 6, 7). 
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 In this study, Kmax showed a gradual flattening in comparison with 
the pre-operative values at all the post-operative visits in a statistically 
significant manner. Similarly the Kmin also showed a statistically 
significant reduction from the pre-operative values at all post-operative 
visits. The Kavg values also showed a similar trend (Table 7). The 
reduction in Kavg was also found to be statistically significant. 
 In other studies conducted on western population, a similar trend 
was observed. Witting Silva et al. (2008)58 and Hersh et al. (2011)59 
observed a reduction in the value of Kmax at the end of their one-year 
study. Greenstein et al. (2013)56 observed a flattening of the steeper 
meridian (Kmax) in patients with severe disease having K value more than 
55 D. 
 A study conducted by Agrawal et al. (2009)36 in the Indian 
population also observed similar results at the end of one year. These 
results were comparable to that of the present study. Caporossi et al. 
(2010)31 studied the topographic findings and observed the reduction in the 
mean average K in a statistically significant manner over a period of two 
years. This reduction was gradual and statistically significant. 
 Another long term, large sample study by Raiskup et al. (2008)32 
demonstrated similar results. Also, Kankaria et al. (2013)55 noticed a 
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transient worsening in the topographic indices in the early post-operative 
period. These indices stabilized on subsequent visits without any 
intervention.  
 Thus, most studies in the literature cited showed a gradual reduction 
in the keratometric values after C3R. All the visual and topographic 
indices observed over the period of one year after the procedure, showed a 
trend of either halting or partially reversing the disease process. The 
improvement was seen irrespective of the demographical factors, such as 
age, gender and other pre-operative indices such as corneal thickness and 
the average keratometry value (Table 8). 
 In the current study, the eyes which showed an improvement of 
more than 0.50 D were considered to be statistically significant and the 
ones in which the improvement was less than 0.50 D were considered to be 
stable. Out of the 50 eyes in this study, 68% (34 eyes) showed 
improvement, whereas 20% (10eyes) remained stable. However an 
increase in the average K by less than 0.50 D was noted in four eyes. Two 
eyes that developed ulcerative keratitis were excluded in the analysis. This 
indicated that C3R gives a beneficial response to arrest the progression of 
keratoconus overall.  
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Complications 
 A complication rate of 4% (2 eyes) was observed in this study. The 
development of keratitis in both eyes was attributed to the usage of 
bandage contact lens, post-procedure. Both patients were started on topical 
broad spectrum antibiotics. One of the patients showed improvement 
whereas the other patient who did not respond to topical therapy, required 
penetrating  keratoplasty. On culture report, the organism was found to be 
Staphylococcus aureus. 
 Sharma N et al. (2010)48 observed a case of pseudomonas keratitis 
after C3R procedure. This was an isolated case report. Gautham et al. 
( 2013)62 reported a case of infectious keratitis due to Microsporidium 
after collagen crosslinking (CXL). A few other complications were 
reported in studies by Bakshi et al. (2012)63. They had a patient who 
developed corneal haze following C3R. This resolved on treatment with 
topical steroid therapy.  
 Similarly in the Sienna CXL trial by Caporossi et al. (2010)31, 9.8% 
patients were found to have moderate corneal haze which resolved without 
treatment; this haze was not found to be visually significant.  
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 Koller et al.(2009)52 demonstrated  an increased risk of 
complications and increased failure rates in patients of  age more than 35 
years and Kmax value more than 58 D undergoing  C3R. This indicates 
that the procedure should not be delayed for a long period of time and 
ideally should be performed at the time of presentation for the best results. 
Other studies like the one by Chatzis and Hafezi at al., (2012)51 did not 
observe any visually significant complication. 
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SUMMARY 
 
 Corneal collagen cross-linking with riboflavin is a simple, safe and 
an effective technique which is fast emerging as a treatment modality for 
corneal ectasia. The aim of this study was to evaluate the safety and 
efficacy of corneal collagen cross-linking in keratoconus and its role in 
preventing the disease progression.  
 The outcome measures evaluated were uncorrected visual acuity, 
best corrected visual acuity, spherical equivalent, cylindrical error, 
keratometry values (Kmax, Kmin, Kavg), and the rate of development of 
complications, if any. 
 The current investigation was a prospective interventional study on 
patients with keratoconus who presented to the Cornea Clinic, Institute of 
Ophthalmology, Joseph Eye Hospital, Tiruchirapalli, Tamilnadu over a 20 
month period (April 2011 to November 2012). 
 Fifty eyes of 38 patients, comprising 20 males (53%) and 18 females 
(47%) with a  mean age of 19.2 ± 4.5 years (range: 11-25 years), who 
presented with progressive keratoconus during the study period, who 
satisfied the inclusion criteria and who provided consent for undergoing 
C3R were enrolled in the study. 
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 Among them, 16 eyes (32%) had stage I keratoconus, 23 (46%) eyes 
had stage II keratoconus, and 11 eyes (22%) had stage III keratoconus, 
based on the Krumeich classification (50). 
 Twenty six patients (68%) underwent C3R in one eye and 12 
patients (32%) in both eyes with the severe eye treated first. 
 The mean UCVA before treatment was 0.18 ± 0.16 (in decimals) 
(6/60-6/36), and the mean UCVA at the end of one month after C3R was 
0.20 ± 0.17(6/36); this improvement was statistically significant (p=0.05) 
(Table1). The visual acuity continued to improve at 6 months (0.26 ± 0.19 
(6/24); p <0.0001) and at one year of follow up (0.32 ± 0.22(6/18);  
(p <0.0001).Thus, there was statistically significant improvement in mean 
UCVA at all visits post-C3R (Table 1). 
 The mean BCVA pre-treatment was 0.51 ± 0.27(6/12), and  
post-C3R (one month) it was 0.52 ± 0.25(6/12); p=0.66), this improvement 
was not of statistical significance (Table 2).However, BCVA showed 
statistically significant improvement at six months (0.63 ± 0.25(6/12-6/9); 
(p <0.0001), and at one year  (0.76 ± 0.22(6/9-6/6);  p <0.0001),  
post-treatment compared with the pre-treatment data, reaching its 
maximum at one year with mean BCVA of 0.76 ± 0.22 (in decimals) (6/9-
6/6), (p <0.0001) (Table 2). 
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 The baseline mean SE was -4.60 D (SD ± 2.99), (Table 3). The 
mean SE was found to have reduced to -4.45 D (SD ± 2.85) at one month 
following C3R; however this reduction was not statistically significant   
(p =0.35). Further reduction in SE value compared to baseline mean SE 
was noted at the end of 6 months (-3.97 D (SD ± 2.60); p =0.001); and at 
one year (-3.63 D (SD ± 2.70); p=0.001) (Table 3). Thus the mean SE 
decreased during the follow-up period, with the difference from the 
baseline reaching statistical significance at 6 months and one year.  
(p =0.001) (Table 3). 
 The mean cylinder value at baseline was -3.70 D (SD ± 1.86), and 
reduction in the cylinder value throughout the one year follow- up period 
was observed post treatment (Table 4). The mean cylinder value at the end 
of one month was -3.18 D (SD ± 1.4); p=0.01), at 6 months was -2.71D 
(SD ± 1.52); p<0.0001); and at one year was -2.39 D (SD ± 1.40), 
(p<0.0001) (Table 4). 
 This reduction in mean cylinder value from baseline throughout the 
follow-up at one month, 6 months and  at one year  post-C3R was found to 
be statistically significant at all post-operative visits (p<0.0001) (Table 4). 
 The mean keratometry value of the steeper meridian (Kmax) at 
baseline was 53.49 D (SD ± 4.35), (range: 47 - 60.25 D).The mean 
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keratometry value of the flatter meridian( Kmin) was 47.41 D (SD ± 3.50) 
(range: 45.12 - 56.12  D).The mean average keratometry value (Kavg) was 
50.45 D (SD ± 3.75) (range: 47.25-57.62 D).There was statistically 
significant improvement in these parameters in comparison to the baseline 
during the follow-up period. 
 The mean keratometry value of the steeper meridian (Kmax) at 
baseline was 53.49 D (SD ± 4.35), (range: 47 - 60.25 D) (Table 5). The 
mean Kmax at one month post-treatment was found to have reduced to 
52.37 D (SD ± 8.68; p=0.001).There was further reduction at 6 months   
( 51.94 D (SD ± 8.75), p <0.0001); and at one year ( 51.67 D (SD ± 8.76); 
(p <0.0001) (Table 5).  
 This reduction in the Kmax value from baseline was statistically 
significant at all post-operative visits (p <0.0001). 
 The quantum of reduction in the mean K max value compared to the 
baseline was 0.14 D at one month, 0.63 D at six months and was 0.90 D at 
one year (Table 5). 
 The mean keratometry value of the flatter meridian (Kmin) was 
47.41 D (SD ± 3.50) (range: 45.12 - 56.12  D) prior to treatment (Table 6). 
At one month post-C3R, the Kmin value was 46.41 D (SD ± 7.53); 
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(p=0.001), and at 6 months post-C3R was 46.09 D (SD ± 7.53); p <0.0001) 
and at one year post-C3R was 45.91 D (SD ± 7.53); p <0.0001). This 
constant reduction in Kmin value from baseline throughout the follow-up 
period was statistically significant (p <0.0001). 
 The quantum of reduction of the mean Kmin value was found to be 
0.11 D at one month, 0.44 D at 6months , and 0.63 D at one year  
follow-up, respectively (Table 6). 
 The mean average keratometry value (Kavg) at baseline was 50.45D 
(SD ± 3.75) (range: 47.25-57.62 D) (Table 7).There was reduction in Kavg 
value at one month post-C3R to 49.39 D (SD ± 8.03), and this reduction 
was statistically significant (p =0.002). On follow-up, the Kavg value was 
found to be further reduced to 49.01 D (SD ± 8.06), p <0.0001) at 6 
months, and to 48.79 D (SD ± 8.06), p<0.0001) at one year post-C3R 
(Table 7). This reduction in Kavg value on follow-up was of statistical 
significance. 
 This study also recorded a reduction in the mean Kavg value 
compared to the baseline values during the follow-up, by a mean of 0.12 D 
at one month, 0.54 D at 6 months, and 0.77 D at one year post-C3R. 
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 In this study, eyes that showed reduction in Kavg value by more 
than 0.5 D from the baseline, at the end of one year follow-up  was 
considered improved and those eyes which showed reduction of less than 
0.5 D were considered stable. 
 Thirty-four eyes showed improvement and 10 eyes remained stable 
at the end of one year follow-up in this study. Out of the 50 eyes in this 
study, 68% (34 eyes) showed improvement, whereas 20% (10eyes) 
remained stable. However an increase in the average K by less than 0.50 D 
was noted in four eyes. Two eyes that developed keratitis were excluded in 
this analysis. This indicated that C3R gives a beneficial response to arrest 
the progression of keratoconus overall.  
 And also, gradual reduction in the keratometric values was observed 
throughout the follow-up period post-C3R. All the visual and topographic 
indices observed over the period of one year after the procedure, showed a 
trend of either halting or partially reversing the disease process. The 
improvement was seen irrespective of the demographical factors such as 
age, gender and other pre-operative indices such as corneal thickness and 
the average keratometry value (Table 8). 
 In this study, two patients developed complications in the form of 
corneal ulcer within the first month of the procedure. Both the patients 
73 
were started on topical broad spectrum antibiotics. On further follow-up, 
one patient improved, but corneal scarring occurred with resultant 
steepening of average K values. On the other hand, in the other patient, the 
ulceration progressed necessitating   therapeutic penetrating keratoplasty. 
Thus complications were noted in only two (4%) of 50 eyes in this study, 
and this was attributed to the use of bandage contact lens post- procedure. 
 This study found C3R to be an effective method for treating 
keratoconus providing good functional outcome in terms of visual and 
topographic parameters. These results were comparable to that of other 
studies so far conducted. However, a small sample size and short  
follow-up period were limiting factors of the current study. 
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CONCLUSION 
 In the current study, which aimed at evaluating the safety and 
efficacy of corneal collagen cross-linking with riboflavin (C3R) in 
keratoconus patients, the following conclusions were made. 
 The uncorrected visual acuity improved significantly from the 
baseline till one year of follow-up in all treated eyes. However, the best 
corrected visual acuity and the mean spherical equivalent showed a gradual 
improvement which was of statistical significance only at six months and 
one year of follow-up. This suggested delayed stabilization of the visual 
acuity, post-C3R. 
 This study also observed statistically significant reduction in the 
mean cylinder value throughout the follow- up period. 
 The topographic indices such as, the Kmax, Kmin and Kavg showed 
a gradual flattening in all the post-operative visits in a statistically 
significant manner.  
 The improvement was seen irrespective of the demographical factors 
such as age, gender and other pre-operative indices like corneal thickness 
and the average keratometry value. 
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 All the visual and topographic indices observed over the period of 
one year after the procedure, showed a trend of either halting or partially 
reversing the disease process.  
 Thus, corneal collagen cross-linking with riboflavin is a simple, safe 
and an effective modality of treatment for progressive keratoconus with 
good success rate and minimal incidence of complications. However, 
longer follow-up is required for assessing the durability of this procedure 
and its long term side effects. 
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Name:                                                            MRD No: 
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Chief Complaints:  
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Other associated systemic diseases: 
 
Baseline parameters: 
 
 Eye   RE   LE 
  Right eye  Left eye 
Uncorrected Visual 
Acuity(UCVA) 
  
Best Corrected Visual 
Acuity(BCVA) 
 
 
 
DSPH   
DCYL   
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 Pre-operative data: 
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 Lens  
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Astigmatism 
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Date of Procedure: 
 
 
Post-operative data : 
 
  Follow up  
after 1 month 
Follow up 
after 6 
month 
Follow up 
after 1year 
Vision RE    
 LE    
RE BCVA    
 DSPH    
 DCYL    
 AR    
LE BCVA    
 DSPH    
 DCYL    
 AR    
K1     
K2      
Avg K     
Astigmatism     
CIM     
Complication     
 
 
 

UCVA BCVA Dsph Dcyl Axis SE K1 K2 Avg K UCVA BCVA Dsph Dcyl Axis SE K1 K2 Avg K UCVA BCVA Dsph Dcyl Axis SE K1 K2 Avg K
P695287 15 M RE 5/60 6/18 -4 -2 180 -5 56.37 47.25 51.81 472 6/60 6/24 -3.5 -2 180 -4.5 55.87 47.15 51.51 6/36 6/18 -3 -2 180 -4 55.67 46.75 51.21 6/24 6/12 -2 -1.5 180 -2.75 55.27 46.5 50.885
P751409 12 M RE 6/18 6/9 -2 -6 40 -5 54.5 46.75 50.625 449 6/18 6/9 -2 -5 30 -4.5 54.5 46.25 50.375 6/12 6/9 -2 -5 30 -4.5 54.25 46 50.125 6/9 6/6p -1 -4 30 -3 55 45.81 50.405
P751409 12 M LE 6/60 6/12p -2 -4.25 170 -4.125 60.12 56.12 58.12 402 6/24 6/18 -2 -4.25 170 -4.125 59.82 56.12 57.97 6/60 6/18 -3.5 -3.25 160 -5.125 0 0 0 6/18 6/9 -1.5 -3.25 160 -3.125 0 0 0
P751931 21 M RE 2/60 6/60 -9 -4.5 30 -11.25 58.75 51.37 55.06 436 6/60 6/36 -9 -4.5 30 -11.25 58.5 51.25 54.875 6/36 6/24 -8 -4 30 -10 57.75 51 54.375 6/24 6/18 -8 -3.5 30 -9.75 57.5 50.62 54.06
P761222 21 M LE 6/24 6/12 -1.5 -5.5 180 -4.25 51.12 43.75 47.435 500 6/24 6/12p -0.75 -6 155 -3.75 51.25 43.62 47.435 6/18 6/9 -0.75 -5.5 160 -3.5 51.12 43.6 47.36 6/12 6/9 -0.75 -5 160 -3.25 51 43.6 47.3
P771475 24 M RE 6/60 6/18 -6 -3 155 -7.5 51 46.75 48.875 498 6/60 6/9 -6 -3 160 -7.5 50.37 46.12 48.245 6/60 6/9 -6 -3 160 -7.5 49.75 45.25 47.5 6/60 6/9 -6 -3 160 -7.5 49.5 45 47.25
P774377 25 M RE 6/60 6/18 -1.5 -4 30 -3.5 56.25 48.62 52.435 424 6/36 6/12p -2 -5 35 -4.5 56.12 48.62 52.37 6/36 6/9 -2 -5 35 -4.5 55.75 48.75 52.25 6/36 6/9 -2 -2 30 -3 55.87 48.25 52.06
P799854 11 M LE 6/24 6/9 -2.5 -3 170 -4 53.87 47.25 50.56 482 6/24 6/9 -2.5 -3 170 -4 53.62 47.12 50.37 6/18 6/6p -2 -3 170 -3.5 53.5 47.12 50.31 6/18 6/6 -2 -3 170 -3.5 53.25 47 50.125
P800768 19 M LE 6/18 6/9 -3 -2 180 -4 50.72 46.87 48.795 456 6/18 6/9 -3 -2 170 -4 51.37 47.87 49.62 6/18 6/9 -3 -1.75 170 -3.875 50.75 47 48.875 6/12p 6/6p -3 -1.5 170 -3.75 50.12 48.75 49.435
P801200 20 M LE 5/60 6/9 -3.5 -3 115 -5 47.5 43.37 45.435 484 6/60 6/9 -3.5 -3 100 -5 47.45 43.35 45.4 6/36 6/9 -2 -3 100 -3.5 47.25 43.25 45.25 6/24p 6/6p -1.5 -3 100 -3 46.75 42.85 44.8
P801200 20 M RE 6/60 6/6 -3.5 -1 60 -4 45 42.75 43.875 502 6/36 6/6p -3.5 -1 60 -4 44.85 42.65 43.75 6/24 6/6p -3.5 -1 60 -4 44.5 42.5 43.5 6/12 6/6p -3.5 -0.75 70 -3.875 44.12 42.5 43.31
P806124 21 M LE 6/36p 6/24 0 -6 170 -3 57.37 45.87 51.62 451 6/24 6/18 -1 -5.5 170 -3.75 57.12 45.75 51.435 6/18 6/12 -1 -5.5 170 -3.75 56.75 45.5 51.125 6/12 6/6p -1 -5 160 -3.5 56.5 45.35 50.925
P814272 24 M LE 3/60 6/18 -4.5 -3 170 -6 53.37 50.62 51.995 456 6/60 6/9p -4.5 -3 5 -6 54.75 50.25 52.5 6/60 6/12 -4.5 -3 180 -6 55 49.87 52.435 6/60 6/9 -4.25 3 180 -2.75 54.75 49.75 52.25
P815487 23 M LE 6/60 6/12p -6 -5 180 -8.5 59.87 50.25 55.06 454 6/60 6/12 -6 -5 180 -8.5 59.75 50.12 54.935 6/36 6/9 -5 -4 180 -7 59.5 50.12 54.81 6/24 6/9 -5 -4 180 -7 59.4 49.8 54.6
P815487 23 M RE 6/9 6/6p -1.25 -2.5 170 -2.5 52.75 45.62 49.185 475 6/9 6/6p -1.25 -2.5 170 -2.5 52.6 45.5 49.05 6/9 6/6p -1 2.5 170 0.25 52.5 45.52 49.01 6/9 6/6 -1 -2 180 -2 52.35 45.12 48.735
P820504 20 M RE 5/60 6/9 -2.5 -3.5 20 -4.25 50.25 45.37 47.81 504 6/60 6/24 -2 -3.5 30 -3.75 49.85 45.15 47.5 6/36 6/9p -2 -3 30 -3.5 49.5 44.85 47.175 6/36 6/6 -2 -3 40 -3.5 48.75 44.5 46.625
P820504 20 M LE 5/60 6/9p -2 -3 135 -3.5 48.5 44.37 46.435 512 6/60 6/18p -2 -3 140 -3.5 48.25 43.75 46 6/36 6/9p 0 -3 150 -1.5 47.15 43.5 45.325 6/18 6/6p 0 -2.5 130 -1.25 46.75 43.5 45.125
P822730 13 M RE 5/60 6/60 -10 -5 5 -12.5 60.25 56.12 58.185 446 6/60 6/18 -14 0 0 -14 60.12 55.75 57.935 6/36 6/18 -12 0 0 -12 59.25 55.12 57.185 6/36 6/12p -14 -2 60 -15 58.72 55.12 56.92
P835473 24 M RE 6/24p 6/9p 0 -2 140 -1 46.75 42.12 44.435 420 6/12 6/9 0 -2 140 -1 46.5 41.7 44.1 6/9 6/6 0 -1 140 -0.5 46.15 41.25 43.7 6/6p 6/6 0 -1 140 -0.5 45.75 41.25 43.5
P840452 15 M LE 6/18p 6/9 0 -4 60 -2 57.75 49 53.375 490 6/18 6/9 0 -3.5 90 -1.75 57.5 48.75 53.125 6/12p 6/6p 0 -3.5 90 -1.75 56.75 48.25 52.5 6/9 6/6 0 -3 90 -1.5 56.5 47.85 52.175
P842462 20 M LE 3/60 6/9 -8 -8 180 -12 60.37 52.25 56.31 454 6/60 6/9 -8 -6 180 -11 60.12 52 56.06 6/60 6/9 -8 -4 180 -10 59.85 51.75 55.8 6/60 6/9 -8 -4 180 -10 59.5 51.5 55.5
P842462 20 M RE 5/60 6/9 -8 -3 15 -9.5 55.25 50.12 52.685 492 6/60 6/9 -8 -3 140 -9.5 55 49.85 52.425 6/60 6/9 -7 -3 140 -8.5 54.75 49.65 52.2 6/60 6/9 -7 -2.5 140 -8.25 54.5 49.35 51.925
P842546 15 M RE 6/60 6/24 -3 -3 180 -4.5 52.25 45.62 48.935 511 6/60 6/18 -3 -3 180 -4.5 51.75 45.6 48.675 6/36 6/18 -3 -2 180 -4 50.83 45.61 48.22 6/24 6/12 -3 -1 180 -3.5 50.68 45.06 47.87
P842546 15 M LE 6/24 6/12p -1 2.75 150 0.375 52.5 45.12 48.81 521 6/24 6/12 -1 -2.5 150 -2.25 52.33 45.18 48.755 6/18 6/9p -1 -2 150 -2 51.75 44.5 48.125 6/18 6/9 -1 -2 150 -2 51.5 44.5 48
P855286 13 M RE 3/60 6/36 -7 -5 180 -9.5 57.37 49.37 53.37 421 6/60 6/12 -4.5 -3.5 180 -6.25 56.75 48.75 52.75 6/60 6/9p -4.5 -3 180 -6 56.5 48.25 52.375 6/60 6/9p -3.5 -3 20 -5 56.37 47.2 51.785
P840368 19 M LE 6/24 6/12 -2 -2.5 160 -3.25 55.25 46.25 50.75 420 6/36 6/18 -2 -2.5 160 -3.25 54.85 45.85 50.35 6/18 6/12 -1.75 -0.5 150 -2 54.6 45.5 50.05 6/18 6/9 -0.5 -2 160 -1.5 54.5 45.5 50
P668964 15 F RE 6/12 6/9 0 -3 180 -1.5 58.62 47.62 53.12 520 6/18 6/6p -3 -1 180 -3.5 57.02 47.37 52.195 6/18 6/6 -3 -1 180 -3.5 56.67 47.2 51.935 6/18 6/6 -3 -0.75 180 -3.375 56.35 46.85 51.6
P685745 20 F LE 5/60 6/36 -0.5 -3 180 -2 49.25 45.37 47.31 446 6/36 6/9p -0.5 -3 180 -2 50.75 46.5 48.625 6/36 6/12 -0.75 -3 145 -2.25 49.62 45.62 47.62 6/18 6/9p -0.5 -3 150 -2 48.37 44.25 46.31
P759128 25 F RE 6/12p 6/9 -1.5 -6 35 -4.5 49.5 43.25 46.375 529 6/18 6/9p -1.5 -5 30 -4 49.62 43.5 46.56 6/18 6/9p -1 -4.5 30 -3.25 50.5 44 47.25 6/18 6/9 -1 -4 30 -3 50 42.87 46.435
P761900 25 F RE 3/60 6/18 -5 -5 180 -7.5 48.75 44.12 46.435 506 6/60 6/36 -5 -4 180 -7 48.62 43.87 46.245 6/60 6/18p -3.5 -4 180 -5.5 46 42.12 44.06 6/36 6/18 -3 -3.5 180 -4.75 45.8 42 43.9
P761900 25 F LE 3/60 6/60 -3.5 -5 5 -6 49 44 46.5 507 6/60 6/24 -4 -3.5 5 -5.75 48.75 43.8 46.275 6/60 6/18 -4.5 -3 180 -6 48.37 43.62 45.995 6/36 6/12p -3 -3 180 -4.5 47.85 43.32 45.585
P768581 19 F RE 6/24p 6/12p 0 -2 60 -1 50.75 47.5 49.125 460 6/24 6/12 0 -1.5 70 -0.75 50.87 47.75 49.31 6/24 6/9 0 -2.5 40 -1.25 49.12 46.25 47.685 6/24 6/6p 0 -2 40 -1 49 46.12 47.56
P768581 19 F LE 6/60 6/9p 0 -5 140 -2.5 53.75 48 50.875 439 6/60 6/12p 0 -3 130 -1.5 55.5 48.75 52.125 6/60 6/12p 0 -2.5 140 -1.25 52.12 47.5 49.81 6/36 6/9 0 -2 140 -1 52 47.25 49.625
P779440 23 F RE 6/36 6/6p 0 -4.5 30 -2.25 49.12 44.62 46.87 485 6/18 6/9 0 -4 30 -2 49 44.52 46.76 6/12p 6/6p 0 -3 30 -1.5 48.92 44.52 46.72 6/18 6/6 0 -3 30 -1.5 48.87 44.82 46.845
P779492 13 F RE 6/9 6/6 0 -2.25 170 -1.125 48 44 46 526 6/6 6/6 0 0 0 0 47.75 43.12 45.435 6/6 6/6 0 0 0 0 47.37 43.25 45.31 6/6 6/6 0 0 0 0 47.2 43.12 45.16
P781750 25 F LE 6/60 6/24 -4 -2 140 -5 50 45.87 47.935 537 6/60 6/18 -4 -2 140 -5 49.75 45.5 47.625 6/60 6/18 -3.5 -1 140 -4 48.5 45.65 47.075 6/36 6/12 -3.5 -1 140 -4 48.5 45.55 47.025
P784968 25 F RE 5/60 6/12 -0.75 -8.5 30 -5 53.25 45.12 49.185 460 6/60 6/12p -2.5 -6 25 -5.5 54 45.25 49.625 6/9p 6/6p -3.25 0 0 -3.25 52.5 44.87 48.685 6/9p 6/6p -3.25 0 0 -3.25 52.25 44.75 48.5
P802352 20 F RE 6/36p 6/18 -1.25 -3.5 60 -3 60.27 57.37 58.82 453 6/60 6/18 -1 -3 25 -2.5 60.12 57.1 58.61 6/60 6/18 -1 -3.5 35 -2.75 59.85 56.85 58.35 6/60 6/18 -1 -3 40 -2.5 59.7 56.87 58.285
P802352 20 F LE 5/60 6/9p -1.25 -3.5 130 -3 60.37 54.87 57.62 445 6/60 6/9 -1 -3.5 130 -2.75 60.15 54.25 57.2 6/36 6/9p -1 -3 130 -2.5 59.8 54.15 56.975 6/24 6/9p -1 -3 130 -2.5 59.65 54.1 56.875
P802434 15 F RE 6/60 6/18p -4 -4 10 -6 54.37 48.75 51.56 442 6/60 6/12 -3 -4 10 -5 54.25 48.5 51.375 6/60 6/9p -3 -3.5 10 -4.75 53.87 48.25 51.06 6/36 6/6p -3 -3 180 -4.5 53.37 48 50.685
P802434 15 F LE 6/60 6/18p -2.5 -4 160 -4.5 56.25 48.75 52.5 446 6/60 6/18 -3 -4 160 -5 55.75 48.5 52.125 6/36 6/12 -3 -3.5 160 -4.75 55.78 48.2 51.99 6/36 6/6 -3 -3 160 -4.5 55.5 47.9 51.7
P805990 24 F LE 6/12p 6/6p -2 -1 110 -2.5 47.62 45.25 46.435 472 6/18 6/6 -2 -1.75 110 -2.875 47.32 45.12 46.22 6/9 6/6 -2 -1.5 100 -2.75 46.82 45 45.91 6/9 6/6 -2 0 0 -2 46.52 44.72 45.62
P824626 19 F LE 5/60 6/60 0 -5 140 -2.5 52.87 46.5 49.685 476 6/60 6/12 -4.5 -3 150 -6 52.37 46.5 49.435 6/60 6/12 0 -3 120 -1.5 51.37 44.62 47.995 6/60 6/12 -1 -3 130 -2.5 51.17 44.52 47.845
P831595 12 F RE 6/60 6/12 -3 -4 20 -5 58.87 47.12 52.995 450 6/24 6/18 -2 -3 20 -3.5 58.75 47.87 53.31 6/24 6/12 -2 -3.5 20 -3.75 57.62 47.5 52.56 6/24 6/9p -1.5 -3 40 -3 58.75 47.5 53.125
P831595 12 F LE 6/60 6/24 0 -3 180 -1.5 57.62 47.37 52.495 462 6/36 6/18 0 -3 180 -1.5 58 47.5 52.75 6/36 6/12p 0 -2.5 180 -1.25 58.37 47.25 52.81 6/36 6/12 0 -2.5 120 -1.25 57.75 46.87 52.31
P842108 12 F RE 6/24 6/9p -0.5 -4.5 70 -2.75 48.62 44.12 46.37 531 5/60 6/60 0 0 0 0 0 0 0 6/60 6/18 -4 -3.5 30 -5.75 63.25 56.87 60.06 6/36 6/12 -3 -2.5 60 -4.25 63.12 56.87 59.995
P842108 12 F LE 5/60 6/60 -8 -7 140 -11.5 57.25 51.12 54.185 491 6/36p 6/18 -5.5 -5 130 -8 57.15 50.87 54.01 6/24p 6/12 -5 -4 130 -7 57 50.87 53.935 6/24 6/9p -3.5 -3 120 -5 56.25 51.62 53.935
P849401 24 F RE 6/60 6/18 -2 -3.5 60 -3.75 52.12 46.12 49.12 470 6/60 6/12p -2.5 -3.5 65 -4.25 49.8 45.75 47.775 6/36 6/12 -1 -3 45 -2.5 49.75 45.5 47.625 6/18 6/9 -1 -2.5 130 -2.25 49.25 45.25 47.25
P856276 20 F RE 6/60 6/12 -3 -3 20 -4.5 55.87 48.75 52.31 454 6/60 6/18 -2 -3.5 30 -3.75 55.25 48.87 52.06 6/60 6/12 -2.5 -3.5 90 -4.25 55.87 49.12 52.495 6/60 6/12 -3 -3.5 90 -4.75 55.37 49 52.185
P856276 20 F LE 6/60 6/9 -1 -2 130 -2 47.25 45.87 46.56 488 6/36 6/9 -1 -1.5 130 -1.75 46.85 45.57 46.21 6/18 6/6p 0 -1.5 130 -0.75 46.75 45.27 46.01 6/18 6/6 0 -1 130 -0.5 46.25 45 45.625
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